DOCSLIB.ORG

Dept. of Molecular Medicine (MOMA), Aarhus University Hospital, Denmark Disorders of Sex Development (DSD) V1, 2021-03-22, 86 Genes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dept. of Molecular Medicine (MOMA), Aarhus University Hospital, Denmark Disorders of Sex Development (DSD) V1, 2021-03-22, 86 Genes Dept. of Molecular Medicine (MOMA), Aarhus University Hospital, Denmark Disorders of Sex Development (DSD) v1, 2021-03-22, 86 genes Approved symbol Approved Name HGNC ID Location AKR1C2 aldo-keto reductase family 1 member C2 HGNC:385 10p15.1 AKR1C4 aldo-keto reductase family 1 member C4 HGNC:387 10p15.1 AMH anti-Mullerian hormone HGNC:464 19p13.3 AMHR2 anti-Mullerian hormone receptor type 2 HGNC:465 12q13.13 AR androgen receptor HGNC:644 Xq12 AKR1B1 aldo-keto reductase family 1 member B HGNC:381 7q33 ARX aristaless related homeobox HGNC:18060 Xp21.3 ATF3 activating transcription factor 3 HGNC:785 1q32.3 ATP6V0A4 ATPase H+ transporting V0 subunit a4 HGNC:866 7q34 ATRX ATRX chromatin remodeler HGNC:886 Xq21.1 BMP15 bone morphogenetic protein 15 HGNC:1068 Xp11.22 CBX2 chromobox 2 HGNC:1552 17q25.3 CDKN1C cyclin dependent kinase inhibitor 1C HGNC:1786 11p15.4 CHD7 chromodomain helicase DNA binding protein 7 HGNC:20626 8q12.2 CUL4B cullin 4B HGNC:2555 Xq24 CYB5A cytochrome b5 type A HGNC:2570 18q22.3 CYP11A1 cytochrome P450 family 11 subfamily A member 1 HGNC:2590 15q24.1 CYP11B1 cytochrome P450 family 11 subfamily B member 1 HGNC:2591 8q24.3 CYP17A1 cytochrome P450 family 17 subfamily A member 1 HGNC:2593 10q24.32 CYP19A1 cytochrome P450 family 19 subfamily A member 1 HGNC:2594 15q21.2 CYP21A2 cytochrome P450 family 21 subfamily A member 2 HGNC:2600 6p21.33 DGKQ diacylglycerol kinase theta HGNC:2856 4p16.3 DHCR7 7-dehydrocholesterol reductase HGNC:2860 11q13.4 DHH desert hedgehog signaling molecule HGNC:2865 12q13.12 DHX37 DEAH-box helicase 37 HGNC:17210 12q24.31 DMRT1 doublesex and mab-3 related transcription factor 1 HGNC:2934 9p24.3 DYNC2H1 dynein cytoplasmic 2 heavy chain 1 HGNC:2962 11q22.3 EMX2 empty spiracles homeobox 2 HGNC:3341 10q26.11 ERAL1 Era like 12S mitochondrial rRNA chaperone 1 HGNC:3424 17q11.2 ESR1 estrogen receptor 1 HGNC:3467 6q25.1-q25.2 ESR2 estrogen receptor 2 HGNC:3468 14q23.2-q23.3 FGF9 fibroblast growth factor 9 HGNC:3687 13q12.11 FGFR2 fibroblast growth factor receptor 2 HGNC:3689 10q26.13 FOXL2 forkhead box L2 HGNC:1092 3q22.3 GATA4 GATA binding protein 4 HGNC:4173 8p23.1 GLI2 GLI family zinc finger 2 HGNC:4318 2q14.2 HHAT hedgehog acyltransferase HGNC:18270 1q32.2 HOXA13 homeobox A13 HGNC:5102 7p15.2 Page 1 of 3 Dept. of Molecular Medicine (MOMA), Aarhus University Hospital, Denmark Disorders of Sex Development (DSD) v1, 2021-03-22, 86 genes HSD17B2 hydroxysteroid 17-beta dehydrogenase 2 HGNC:5211 16q23.3 HSD17B3 hydroxysteroid 17-beta dehydrogenase 3 HGNC:5212 9q22.32 HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 HGNC:5218 1p12 INPP5E inositol polyphosphate-5-phosphatase E HGNC:21474 9q34.3 PMPCA peptidase, mitochondrial processing subunit alpha HGNC:18667 9q34.3 INSL3 insulin like 3 HGNC:6086 19p13.11 LHB luteinizing hormone subunit beta HGNC:6584 19q13.33 LHCGR luteinizing hormone/choriogonadotropin receptor HGNC:6585 2p16.3 MAMLD1 mastermind like domain containing 1 HGNC:2568 Xq28 MAP3K1 mitogen-activated protein kinase kinase kinase 1 HGNC:6848 5q11.2 MCM5 minichromosome maintenance complex component 5 HGNC:6948 22q12.3 MYRF myelin regulatory factor HGNC:1181 11q12.2 NEK1 NIMA related kinase 1 HGNC:7744 4q33 NR0B1 nuclear receptor subfamily 0 group B member 1 HGNC:7960 Xp21.2 NR2F2 nuclear receptor subfamily 2 group F member 2 HGNC:7976 15q26.2 NR3C1 nuclear receptor subfamily 3 group C member 1 HGNC:7978 5q31.3 NR5A1 nuclear receptor subfamily 5 group A member 1 HGNC:7983 9q33.3 NUP107 nucleoporin 107 HGNC:29914 12q15 PAX6 paired box 6 HGNC:8620 11p13 PAX8 paired box 8 HGNC:8622 2q14.1 PBX1 PBX homeobox 1 HGNC:8632 1q23.3 POR cytochrome p450 oxidoreductase HGNC:9208 7q11.23 PORCN porcupine O-acyltransferase HGNC:17652 Xp11.23 PPP1R12A protein phosphatase 1 regulatory subunit 12A HGNC:7618 12q21.2-q21.31 RPL10 ribosomal protein L10 HGNC:10298 Xq28 RPL15 ribosomal protein L15 HGNC:10306 3p24.2 RSPO1 R-spondin 1 HGNC:21679 1p34.3 RXFP2 relaxin family peptide receptor 2 HGNC:17318 13q13.1 SAMD9 sterile alpha motif domain containing 9 HGNC:1348 7q21.2 SEMA3E semaphorin 3E HGNC:10727 7q21.11 SGPL1 sphingosine-1-phosphate lyase 1 HGNC:10817 10q22.1 SOX10 SRY-box transcription factor 10 HGNC:11190 22q13.1 SOX3 SRY-box transcription factor 3 HGNC:11199 Xq27.1 SOX9 SRY-box transcription factor 9 HGNC:11204 17q24.3 SRD5A2 steroid 5 alpha-reductase 2 HGNC:11285 2p23.1 SRY sex determining region Y HGNC:11311 Yp11.2 STAR steroidogenic acute regulatory protein HGNC:11359 8p11.23 GUCY2C guanylate cyclase 2C HGNC:4688 12p12.3 TAF4B TATA-box binding protein associated factor 4b HGNC:11538 18q11.2 Page 2 of 3 Dept. of Molecular Medicine (MOMA), Aarhus University Hospital, Denmark Disorders of Sex Development (DSD) v1, 2021-03-22, 86 genes PAPPA-AS1 PAPPA antisense RNA 1 HGNC:35152 9q33.2 TCF12 transcription factor 12 HGNC:11623 15q21.3 TOE1 target of EGR1, exonuclease HGNC:15954 1p34.1 TSPYL1 TSPY like 1 HGNC:12382 6q22.1 TWIST2 twist family bHLH transcription factor 2 HGNC:20670 2q37.3 WNT4 Wnt family member 4 HGNC:12783 1p36.12 WT1 WT1 transcription factor HGNC:12796 11p13 ZFPM2 zinc finger protein, FOG family member 2 HGNC:16700 8q23 ZNRF3 zinc and ring finger 3 HGNC:18126 22q12.1 Page 3 of 3.
Load more

Recommended publications
  • Association Between Two Polymorphisms in the SRD5A2 Gene and Serum Androgen Concentrations in British Men1
    578 Vol. 12, 578–581, June 2003 Cancer Epidemiology, Biomarkers & Prevention Short Communication Association between Two Polymorphisms in the SRD5A2 Gene and Serum Androgen Concentrations in British Men1 Naomi E. Allen,2 Juergen K. V. Reichardt, are needed to additionally clarify the role of the A49T Hannah Nguyen, and Timothy J. Key polymorphism in androgen metabolism. Cancer Research United Kingdom Epidemiology Unit, University of Oxford, Gibson Building, Radcliffe Infirmary, Oxford, OX2 6HE, United Kingdom Introduction [N. E. A., T. J. K.], and Institute for Genetic Medicine, Departments of Biochemistry and Molecular Biology and Preventive Medicine, University of It is well established that the steroid 5 ␣-reductase type II Southern California School of Medicine, University of Southern California, enzyme, which irreversibly converts testosterone to its more Los Angeles, California 90089-9075 [J. K. V. R., H. N.] potent metabolite DHT3 in prostatic cells, is required for the normal growth and development of the prostate gland (1). A meta-analysis of prospective studies suggests that the serum Abstract concentration of A-diol-g, a serum marker of the abundance of Androgens are essential for the growth of the prostate 5 ␣-reductase type II and intraprostatic DHT, is slightly higher gland and have been implicated in the development of in men who subsequently develop prostate cancer compared prostate cancer. Little is known about the determinants with healthy individuals (2). The circulating A-diol-g concen- of androgen levels in men, although observed ethnic tration is believed to be a more accurate serum marker of 5 differences suggest they may have a genetic basis.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Effects on Steroid 5-Alpha Reductase Gene Expression of Thai Rice Bran Extracts and Molecular Dynamics Study on SRD5A2
    biology Article Effects on Steroid 5-Alpha Reductase Gene Expression of Thai Rice Bran Extracts and Molecular Dynamics Study on SRD5A2 Chiranan Khantham 1 , Wipawadee Yooin 1,2 , Korawan Sringarm 2,3 , Sarana Rose Sommano 2,4 , Supat Jiranusornkul 1, Francisco David Carmona 5,6 , Wutigri Nimlamool 7 , Pensak Jantrawut 1,2, Pornchai Rachtanapun 8,9 and Warintorn Ruksiriwanich 1,2,8,* 1 Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; [email protected] (C.K.); [email protected] (W.Y.); [email protected] (S.J.); [email protected] (P.J.) 2 Cluster of Research and Development of Pharmaceutical and Natural Products Innovation for Human or Animal, Chiang Mai University, Chiang Mai 50200, Thailand; [email protected] (K.S.); [email protected] (S.R.S.) 3 Department of Animal and Aquatic Sciences, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand 4 Plant Bioactive Compound Laboratory (BAC), Department of Plant and Soil Sciences, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand 5 Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain; [email protected] 6 Instituto de Investigación Biosanitaria ibs.GRANADA, 18014 Granada, Spain 7 Citation: Khantham, C.; Yooin, W.; Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Sringarm, K.; Sommano, S.R.; [email protected] 8 Cluster of Agro Bio-Circular-Green Industry, Faculty of Agro-Industry, Chiang Mai University, Jiranusornkul, S.; Carmona, F.D.; Chiang Mai 50100, Thailand; [email protected] Nimlamool, W.; Jantrawut, P.; 9 School of Agro-Industry, Faculty of Agro-Industry, Chiang Mai University, Chiang Mai 50100, Thailand Rachtanapun, P.; Ruksiriwanich, W.
    [Show full text]
  • Crystal Structure of Steroid Reductase SRD5A Reveals Conserved Steroid Reduction Mechanism
    ARTICLE https://doi.org/10.1038/s41467-020-20675-2 OPEN Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism Yufei Han 1,9, Qian Zhuang2,9, Bo Sun3,9, Wenping Lv 4,9, Sheng Wang5,9, Qingjie Xiao6, Bin Pang1, ✉ Youli Zhou1, Fuxing Wang1, Pengliang Chi6, Qisheng Wang3, Zhen Li7, Lizhe Zhu 4, Fuping Li8, Dong Deng6 , ✉ ✉ ✉ Ying-Chih Chiang 1 , Zhenfei Li 2 & Ruobing Ren 1 Steroid hormones are essential in stress response, immune system regulation, and repro- 1234567890():,; duction in mammals. Steroids with 3-oxo-Δ4 structure, such as testosterone or progesterone, are catalyzed by steroid 5α-reductases (SRD5As) to generate their corresponding 3-oxo-5α steroids, which are essential for multiple physiological and pathological processes. SRD5A2 is already a target of clinically relevant drugs. However, the detailed mechanism of SRD5A- mediated reduction remains elusive. Here we report the crystal structure of PbSRD5A from Proteobacteria bacterium, a homolog of both SRD5A1 and SRD5A2, in complex with the cofactor NADPH at 2.0 Å resolution. PbSRD5A exists as a monomer comprised of seven transmembrane segments (TMs). The TM1-4 enclose a hydrophobic substrate binding cavity, whereas TM5-7 coordinate cofactor NADPH through extensive hydrogen bonds network. Homology-based structural models of HsSRD5A1 and -2, together with biochemical char- acterization, define the substrate binding pocket of SRD5As, explain the properties of disease-related mutants and provide an important framework for further understanding of the mechanism of NADPH mediated steroids 3-oxo-Δ4 reduction. Based on these analyses, the design of therapeutic molecules targeting SRD5As with improved specificity and therapeutic efficacy would be possible.
    [Show full text]
  • Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway
    International Journal of Molecular Sciences Article Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway Patricia Rodríguez Castaño 1,2, Shaheena Parween 1,2 and Amit V Pandey 1,2,* 1 Pediatric Endocrinology, Diabetology, and Metabolism, University Children’s Hospital Bern, 3010 Bern, Switzerland; [email protected] (P.R.C.); [email protected] (S.P.) 2 Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland * Correspondence: [email protected]; Tel.: +41-31-632-9637 Received: 5 September 2019; Accepted: 16 September 2019; Published: 17 September 2019 Abstract: Turmeric, a popular ingredient in the cuisine of many Asian countries, comes from the roots of the Curcuma longa and is known for its use in Chinese and Ayurvedic medicine. Turmeric is rich in curcuminoids, including curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Curcuminoids have potent wound healing, anti-inflammatory, and anti-carcinogenic activities. While curcuminoids have been studied for many years, not much is known about their effects on steroid metabolism. Since many anti-cancer drugs target enzymes from the steroidogenic pathway, we tested the effect of curcuminoids on cytochrome P450 CYP17A1, CYP21A2, and CYP19A1 enzyme activities. When using 10 µg/mL of curcuminoids, both the 17α-hydroxylase as well as 17,20 lyase activities of CYP17A1 were reduced significantly. On the other hand, only a mild reduction in CYP21A2 activity was observed. Furthermore, CYP19A1 activity was also reduced up to ~20% of control when using 1–100 µg/mL of curcuminoids in a dose-dependent manner. Molecular docking studies confirmed that curcumin could dock onto the active sites of CYP17A1, CYP19A1, as well as CYP21A2.
    [Show full text]
  • Original Article Genetic Polymorphisms in the Androgen Metabolism Pathway and Risk of Prostate Cancer in Low Incidence Malaysian Ethnic Groups
    Int J Clin Exp Med 2015;8(10):19232-19240 www.ijcem.com /ISSN:1940-5901/IJCEM0011564 Original Article Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups Prevathe Poniah1, Zahurin Mohamed2, Yamunah Devi Apalasamy2, Shamsul Mohd Zain2, Shanggar Kuppusamy1, Azad HA Razack1 Departments of 1Surgery, 2Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malay- sia Received June 17, 2015; Accepted September 22, 2015; Epub October 15, 2015; Published October 30, 2015 Abstract: Androgens are involved in prostate cancer (PCa) cell growth. Genes involved in androgen metabolism mediate key steps in sex steroid metabolism. This study attempted to investigate whether single nucleotide poly- morphisms (SNPs) in the androgen metabolism pathway are associated with PCa risk in low incidence Asian ethnic groups. We genotyped 172 Malaysian subjects for cytochrome P450 family 17 (CYP17A1), steroid-5-alpha-reduc- tase, polypeptide 1 and 2 (SRD5A1 and SRD5A2), and insulin-like growth factor 1 (IGF-1) genes of the androgen metabolism pathway and assessed the testosterone, dihydrotestosterone and IGF-1 levels. SNPs in the CYP17A1, SRD5A1, SRD5A2, and IGF-1 genes were genotyped using real-time polymerase chain reaction. Although we did not find significant association between SNPs analysed in this study with PCa risk, we observed however, signifi- cant association between androgen levels and the IGF-1 and several SNPs. Men carrying the GG genotype for SNP rs1004467 (CYP17A1) had significantly elevated testosterone (P = 0.012) and dihydrotestosterone (DHT) levels (P = 0.024) as compared to carriers of the A allele. The rs518673 of the SRD5A1 was associated with prostate spe- cific antigen (PSA) levels.
    [Show full text]
  • ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells Katelyn Powell1, Louie Semaan1, M
    Published OnlineFirst March 9, 2015; DOI: 10.1158/1078-0432.CCR-14-2352 Biology of Human Tumors Clinical Cancer Research ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells Katelyn Powell1, Louie Semaan1, M. Katie Conley-LaComb1, Irfan Asangani2, Yi-Mi Wu2, Kevin B. Ginsburg1, Julia Williams3, Jeremy A. Squire4, Krishna R. Maddipati5, Michael L. Cher1,5,6, and Sreenivasa R. Chinni1,5,6 Abstract Purpose: Intratumoral androgen synthesis in prostate cancer Results: We found that ERG regulated the expression of the ABE contributes to the development of castration-resistant prostate AKR1C3 in prostate cancer cells via direct binding to the AKR1C3 cancer (CRPC). Several enzymes responsible for androgen bio- gene. Knockdown of ERG resulted in reduced AKR1C3 expression, synthesis have been shown to be overexpressed in CRPC, thus which caused a reduction in both DHT synthesis and PSA expres- contributing to CRPC in a castrated environment. The TMPRSS2– sion in VCaP prostate cancer cells treated with 5a-androstane- ERG transcription factor has been shown to be present in primary dione (5a-Adione), a DHT precursor metabolite. Immunohisto- prostate cancer tumors as well as CRPC tumors. We hypothesize chemical staining revealed that ERG was coexpressed with that TMPRSS2–ERG fusions regulate androgen biosynthetic AKR1C3 in prostate cancer tissue samples. enzyme (ABE) gene expression and the production of androgens, Conclusions: These data suggest that AKR1C3 catalyzes the which contributes to the development of CRPC. biochemical reduction of 5a-Adione to DHT in prostate cancer Experimental design: We used a panel of assays, including cells, and that ERG regulates this step through upregulation of lentivirus transduction, gene expression, chromatin immunopre- AKR1C3 expression.
    [Show full text]
  • Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models
    cancers Article Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models Subrata Deb 1 , Steven Pham 2, Dong-Sheng Ming 2, Mei Yieng Chin 2, Hans Adomat 2, Antonio Hurtado-Coll 2, Martin E. Gleave 2,3 and Emma S. Tomlinson Guns 2,3,* 1 Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] 2 The Vancouver Prostate Centre at Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada; [email protected] (S.P.); [email protected] (D.-S.M.); [email protected] (M.Y.C.); [email protected] (H.A.); [email protected] (A.H.-C.); [email protected] (M.E.G.) 3 Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada * Correspondence: [email protected]; Tel.: +1-604-875-4818 Received: 14 August 2018; Accepted: 17 September 2018; Published: 20 September 2018 Abstract: Castration-resistant prostate tumors acquire the independent capacity to generate androgens by upregulating steroidogenic enzymes or using steroid precursors produced by the adrenal glands for continued growth and sustainability. The formation of steroids was measured by liquid chromatography-mass spectrometry in LNCaP and 22Rv1 prostate cancer cells, and in human prostate tissues, following incubation with steroid precursors (22-OH-cholesterol, pregnenolone, 17-OH-pregnenolone, progesterone, 17-OH-progesterone). Pregnenolone, progesterone, 17-OH-pregnenolone, and 17-OH-progesterone increased C21 steroid (5-pregnan-3,20-dione, 5-pregnan-3,17-diol-20-one, 5-pregnan-3-ol-20-one) formation in the backdoor pathway, and demonstrated a trend of stimulating dihydroepiandrosterone or its precursors in the backdoor pathway in LNCaP and 22Rv1 cells.
    [Show full text]
  • Metabolic Enzyme Expression Highlights a Key Role for MTHFD2 and the Mitochondrial Folate Pathway in Cancer
    ARTICLE Received 1 Nov 2013 | Accepted 17 Dec 2013 | Published 23 Jan 2014 DOI: 10.1038/ncomms4128 Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer Roland Nilsson1,2,*, Mohit Jain3,4,5,6,*,w, Nikhil Madhusudhan3,4,5, Nina Gustafsson Sheppard1,2, Laura Strittmatter3,4,5, Caroline Kampf7, Jenny Huang8, Anna Asplund7 & Vamsi K. Mootha3,4,5 Metabolic remodeling is now widely regarded as a hallmark of cancer, but it is not clear whether individual metabolic strategies are frequently exploited by many tumours. Here we compare messenger RNA profiles of 1,454 metabolic enzymes across 1,981 tumours spanning 19 cancer types to identify enzymes that are consistently differentially expressed. Our meta- analysis recovers established targets of some of the most widely used chemotherapeutics, including dihydrofolate reductase, thymidylate synthase and ribonucleotide reductase, while also spotlighting new enzymes, such as the mitochondrial proline biosynthetic enzyme PYCR1. The highest scoring pathway is mitochondrial one-carbon metabolism and is centred on MTHFD2. MTHFD2 RNA and protein are markedly elevated in many cancers and correlated with poor survival in breast cancer. MTHFD2 is expressed in the developing embryo, but is absent in most healthy adult tissues, even those that are proliferating. Our study highlights the importance of mitochondrial compartmentalization of one-carbon metabolism in cancer and raises important therapeutic hypotheses. 1 Unit of Computational Medicine, Department of Medicine, Karolinska Institutet, 17176 Stockholm, Sweden. 2 Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden. 3 Broad Institute, Cambridge, Massachusetts 02142, USA. 4 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
    [Show full text]
  • Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androg
    International Journal of Molecular Sciences Review Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androgen Pathway. Mini-Review and Case Report Marta Sumi ´nska 1,* , Klaudia Bogusz-Górna 1, Dominika Wegner 1 and Marta Fichna 2 1 Department of Pediatric Diabetes and Obesity, Poznan University of Medical Sciences, 60-527 Poznan, Poland; [email protected] (K.B.-G.); [email protected] (D.W.) 2 Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-653 Poznan, Poland; mfi[email protected] * Correspondence: [email protected] Received: 3 June 2020; Accepted: 28 June 2020; Published: 29 June 2020 Abstract: Congenital adrenal hyperplasia (CAH) is the most common cause of primary adrenal insufficiency in children and adolescents. It comprises several clinical entities associated with mutations in genes, encoding enzymes involved in cortisol biosynthesis. The mutations lead to considerable (non-classic form) to almost complete (classic form) inhibition of enzymatic activity, reflected by different phenotypes and relevant biochemical alterations. Up to 95% cases of CAH are due to mutations in CYP21A2 gene and subsequent 21α-hydroxylase deficiency, characterized by impaired cortisol synthesis and adrenal androgen excess. In the past two decades an alternative (“backdoor”) pathway of androgens’ synthesis in which 5α-androstanediol, a precursor of the 5α-dihydrotestosterone, is produced from 17α-hydroxyprogesterone, with intermediate products 3α,5α-17OHP and androsterone, in the sequence and with roundabout of testosterone as an intermediate, was reported in some studies. This pathway is not always considered in the clinical assessment of patients with hyperandrogenism.
    [Show full text]
  • De Novo Androgen Synthesis As a Mechanism Contributing to the Progression of Prostate Cancer to Castration Resistance
    DE NOVO ANDROGEN SYNTHESIS AS A MECHANISM CONTRIBUTING TO THE PROGRESSION OF PROSTATE CANCER TO CASTRATION RESISTANCE by JENNIFER ANN LOCKE B.Sc., The University of British Columbia, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE STUDIES (Experimental Medicine) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) June 2009 © Jennifer Ann Locke, 2009 Abstract Prostate cancer (CaP) is the leading cause of cancer in men affecting 24,700 Canadians each year and the third leading cause of cancer mortality with 4,300 deaths each year. CaP cells are derived from the prostate secretory epithelium and depend on androgen ligand activation of androgen receptor (AR) for survival, growth and proliferation. Androgen deprivation therapy (ADT) through pharmacological methods has been the leading form of CaP therapy since Huggin‟s discovery that castration induced the regression of CaP tumors in 1941. Unfortunately, the cancer often recurs within 2-4 years in what has classically been considered “androgen-independent” (AI) disease. Growing evidence implicates androgens and AR activation in this disease recurrence despite castration, suggesting that this terminology should be more appropriately called “castration-resistant” prostate cancer (CRPC). Firstly, AR is found amplified, overexpressed or mutated in a majority of recurrent cancers as compared to primary cancers and secondly, intratumoral testosterone levels remain the same pre- and post-ADT. Additionally, the measured intratumoral DHT levels are sufficient to activate AR in recurrent CaP cells despite low serum androgen levels suggesting that intratumoral androgens remain important mediators of AR-mediated CaP progression. Previously, we and others discovered that recurrent tumor cells have elevated levels of enzymes in the pathways necessary for androgen synthesis from cholesterol.
    [Show full text]
  • SRD5A2 Gene Steroid 5 Alpha-Reductase 2
    SRD5A2 gene steroid 5 alpha-reductase 2 Normal Function The SRD5A2 gene provides instructions for making an enzyme called steroid 5-alpha reductase 2. This enzyme is involved in processing androgens, which are hormones that direct male sexual development. Specifically, the enzyme is responsible for a chemical reaction that converts the hormone testosterone to a more potent androgen, dihydrotestosterone (DHT), in male reproductive tissues. Testosterone and DHT are essential for the normal development of male sex characteristics. Before birth, testosterone is responsible for the formation of internal male genitalia, including the tubes that collect sperm and carry it out of the testes (the epididymis and vas deferens) and glands that help produce semen (the seminal vesicles). DHT directs the development of the external genitalia, including the penis and scrotum, and the prostate gland. During puberty, these two hormones also play an important role in the development of male secondary sex characteristics such as the growth of facial and body hair, increased muscle mass, and deepening of the voice. Health Conditions Related to Genetic Changes 5-alpha reductase deficiency About 50 mutations in the SRD5A2 gene have been identified in people with 5-alpha reductase deficiency. Most of these mutations change single protein building blocks ( amino acids) in steroid 5-alpha reductase 2. Some of these genetic changes render the enzyme completely inactive. Other mutations reduce but do not eliminate the enzyme's function. As a result of SRD5A2 mutations, the body cannot effectively convert testosterone to DHT in reproductive tissues. A shortage of DHT disrupts the formation of external genitalia before birth.
    [Show full text]